Literature DB >> 25854612

CRIT-LINE: a noninvasive tool to monitor hemoglobin levels in pediatric hemodialysis patients.

Rouba Garro1, Scott Sutherland, Liz Bayes, Steven Alexander, Cynthia Wong.   

Abstract

BACKGROUND: The national average for achieving the KDOQI-recommended hemoglobin (Hgb) target level of 11-12 g/dL is low with the current anemia management protocol of measuring Hgb levels every 2-4 weeks to guide intervention. The objective of this study was to correlate initial Hgb readings from the CRIT-LINE monitor with actual serum Hgb levels in pediatric patients on hemodialysis (HD).
METHODS: Data were collected from pediatric HD patients who had Hgb tests ordered for routine and/or clinical reasons. Hgb concentrations were read with the CRIT-LINE after 0.5 or 1 L of blood had been processed by HD in patients with a body weight of ≤20 or >20 kg, respectively. Ultrafiltration was kept at a minimum until the CRIT-LINE Hgb was read.
RESULTS: In total, 217 Hgb readings from 23 HD patients were analyzed. Results showed a statistically significant correlation between CRIT-LINE readings and laboratory Hgb measurements (r = 0.94, p < 0.0001) using Pearson correlation coefficients for well-distributed data. The mean Hgb levels measured by CRIT-LINE and the laboratory were 11.12 ± 1.63 and 11.31 ± 1.69 g/dL, respectively.
CONCLUSIONS: The CRIT-LINE monitor is an accurate instrument for monitoring Hgb levels in HD patients. Further studies will be needed to evaluate whether using CRIT-LINE Hgb levels to guide anemia management will improve the percentage of children with Hgb levels within target.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25854612     DOI: 10.1007/s00467-014-2986-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  38 in total

1.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

2.  Determining optimum hemoglobin sampling for anemia management from every-treatment data.

Authors:  Adam E Gaweda; Brian H Nathanson; Alfred A Jacobs; George R Aronoff; Michael J Germain; Michael E Brier
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

Review 3.  Impact of hematocrit on morbidity and mortality.

Authors:  A J Collins; J Z Ma; J Ebben
Journal:  Semin Nephrol       Date:  2000-07       Impact factor: 5.299

4.  Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.

Authors:  Steven Fishbane; Jeffrey S Berns
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

Review 5.  Pre-end-stage renal disease care in the United States: a state of disrepair.

Authors:  G T Obrador; P Arora; A T Kausz; B J Pereira
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

Review 6.  The spectrum of cardiovascular disease in children with predialysis chronic kidney disease.

Authors:  Blanche M Chavers; Charles A Herzog
Journal:  Adv Chronic Kidney Dis       Date:  2004-07       Impact factor: 3.620

7.  Cardiovascular disease in pediatric chronic dialysis patients.

Authors:  Blanche M Chavers; Shuling Li; Allan J Collins; Charles A Herzog
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

8.  Chronic dialysis in children and adolescents. The 2001 NAPRTCS Annual Report.

Authors:  Alicia M Neu; P L Martin Ho; Ruth A McDonald; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2002-06-21       Impact factor: 3.714

9.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

Authors:  J W Eschbach; M H Abdulhadi; J K Browne; B G Delano; M R Downing; J C Egrie; R W Evans; E A Friedman; S E Graber; N R Haley
Journal:  Ann Intern Med       Date:  1989-12-15       Impact factor: 25.391

Review 10.  Cardiovascular disease as a late complication of end-stage renal disease in children.

Authors:  Jaap W Groothoff; Marc R Lilien; Nicole C A J van de Kar; Eric D Wolff; Jean Claude Davin
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.